06/02/2016 02:42:10 Cookie Policy +44 (0) 207 0700 961 Free Membership Login

You’ve just added your first Follow! This is a brand new feature that will be at the core of several new tools and personalized information feeds that are coming soon.

You can see your current Follow list as a Monitor list here.

Please continue to add stocks to your Follow list so that when the new tools and feeds roll out, you’ll immediately get to make use of them! We will alert early adopters of the Follow list to these new features first.

Glaxosmithkline Share Chat (GSK)

Share Name Share Symbol Market Type Share ISIN Share Description
Glaxosmithkline LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -11.50p -0.81% 1,401.00p 1,400.00p 1,400.50p 1,422.00p 1,398.50p 1,409.00p 9,961,239 16:35:23
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 23,923.0 10,526.0 174.3 8.0 68,186.56

Glaxosmithkline Share Discussion Threads

Showing 19126 to 19149 of 19150 messages
Post New Message
Chat Pages: 766  765  764  763  762  761  760  759  758  757  756  755  >>
DateSubjectAuthorDiscuss
04/2/2016
13:17
Fair summation imv, and given AZN today it perhaps shows the benefit of a more diversified business.essentialinvestor
04/2/2016
13:10
Nils Pratley : The Guardian 'GlaxoSmithKlineR17;s chief executive, Sir Andrew Witty, won’t easily silence the calls for a breakup of the out-of-fashion pharmaceuticals, vaccines and toothpaste giant – but the company’s decent finish to 2015 should buy him some time to move at his own pace. Underlying earnings per share of 75.7p for 2015 didn’t cover the 80p dividend, but the reinvention of GSK was always going to be the work of several years. Witty was able to promise that new pharma products, meaning those launched over the past three years, will achieve £6bn of sales in 2018, two years ahead of the original target. Breo, the drug that will lead the defence of the respiratory territory when fading blockbuster Advair is hit by generic competition in the US, has overcome its slow start. So far, so good. The breakup argument, as advanced by the fund manager Neil Woodford, hinges on the idea that the sum of GSK’s parts is worth more than the current stock market value. Witty cannot be surprised to hear these cries, since he toyed with the notion of floating off ViiV, the 80%-owned HIV business, a couple of years ago............... .............................. ............But pressing the button now seems pointless. There is no emergency. zzeppo
04/2/2016
08:41
DJN seems to make a lot of errors. Half of their output are corrections to earlier stories. Time for ADFN to supply a better feed?solomon
04/2/2016
08:18
How to make a story ..... DJN headline yesterday as the results came out: GlaxoSmithKline Posts GBP354 Million Net Loss in 4Q Then later, it was time to put a different slant onto the figures: Investors' Fears Eased as Glaxo Posts Solid Resultstradermichael
03/2/2016
20:49
Wall St up now, with oil price rise. Should be a good day tomorrow! zzeppo
03/2/2016
17:08
Must admit I feel the same. Given the small number of posters on here I am pretty sure everyone is aware of Anhars "head in the sand" method - but I am pretty suret the rest of us want to discuss the specifics of the company. My only blue today in a sea of red. This is coming back into favour with the choppy waters ahead. Think I'll wait a bit longer though to judge witty's plans.dr biotech
03/2/2016
17:08
M, I've filtered him/her, just easier. As this is the GSK board it's reasonable to have at least some company specific comment surely.essentialinvestor
03/2/2016
17:03
anhar The information does help to the right people. All because you don't understand, or are not prepared to make the effort, doesn't mean others are in the same boat. Consultants, advisors, and those with a detailed knowledge of drug science and their potential markets will find the information useful in making an investment decision. If you don't need the information fine. If you find information irrelevant, fine. If you find CEOs irrelevant fine. But we know that already, you have said it countless times before. You are a long-playing, stuck record and I am surprised your wife hasn't thumped you over the head because of your verbose repetitiveness.minerve
03/2/2016
17:03
http://www.telegraph.co.uk/finance/newsbysector/pharmaceuticalsandchemicals/12138041/GlaxoSmithKline-boss-company-is-not-headed-for-break-up...-yet.htmlzho
03/2/2016
16:49
Those dope medications have saved my life numerous times... Fine but that was not my point. The point was that I don't believe that getting into the fine detail of their drugs, as many here seem to do, helps with judging GSK as an investment. That has nothing to do with the actual merits of the drugs in health care. And if I have repeated my view, well so what? Maybe new readers haven't seen my comments yet.anhar
03/2/2016
16:25
http://www.theguardian.com/business/2016/feb/03/britain-better-inside-eu-says-glaxosmithkline-andrew-wittyzho
03/2/2016
16:22
Those dope medications have saved my life numerous times. We all are aware you find it irrelevant, you have told us on countless occasions.essentialinvestor
03/2/2016
16:15
Pleased to report that (so far) my recent purchases have gained an average of 110p, plus qualifying for 43p dividend later this month ...... ;0). With that, I'm very interested in ploughing through the reams of tables, learning about the new products and would like to personally thank the CEO ...... ;o) :~) I doubt that many here even understand the dope tables. And if we did, it doesn't help the investment case any. It much more likely makes it harder to judge GSK as an investment, due to getting in too close, not seeing the Woodford the trees. As for CEO's, they are mostly irrelevant.anhar
03/2/2016
14:20
Market response is good so far.rcturner2
03/2/2016
14:14
Yes good news here.tim 3
03/2/2016
14:10
Yep bought the lot I've held at around the 1260 mark ..happy daysbadtime
03/2/2016
14:01
Pleased to report that (so far) my recent purchases have gained an average of 110p, plus qualifying for 43p dividend later this month ...... ;0). With that, I'm very interested in ploughing through the reams of tables, learning about the new products and would like to personally thank the CEO ...... ;o)tradermichael
03/2/2016
13:04
Yep exactly, anhar. Good news for income investors.rcturner2
03/2/2016
12:20
A quick look at the 2015 figures confirms the expected final div of 23p and spec of 20p, both xd on 18 Feb and paid on 14 Apr. They also restate the 80p div expected for 2016 and 17. With the FTSE yielding about 4%, this means GSK on an 80p div would have to be at 2,000p to match that yield, which is my current exit price. It's well below so I continue to hold for income until its yield matches the index or forever, whichever comes first. I have no interest in all the reams of guff in the report about all their pill popping pipelines, who the CEO is and most of the rest of it.anhar
03/2/2016
12:11
That is consumer healthcare impact? if so not relevant imv.essentialinvestor
03/2/2016
12:10
Core op margin -4.8%.eeza
03/2/2016
12:10
80p dividend for 2016 and 2017rcturner2
03/2/2016
12:08
Yup, very difficult to take in on a first glance, special confirmed, which we already knew.essentialinvestor
03/2/2016
12:08
Swing time!tradermichael
Chat Pages: 766  765  764  763  762  761  760  759  758  757  756  755  >>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V: D:20160206 02:42:10